1. Home
  2. JFU vs LITS Comparison

JFU vs LITS Comparison

Compare JFU & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

N/A

Current Price

$2.68

Market Cap

29.9M

Sector

Finance

ML Signal

N/A

LITS

Lite Strategy Inc.

N/A

Current Price

$1.06

Market Cap

25.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JFU
LITS
Founded
2006
2000
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9M
25.7M
IPO Year
2018
2003

Fundamental Metrics

Financial Performance
Metric
JFU
LITS
Price
$2.68
$1.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.1K
318.7K
Earning Date
12-09-2022
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$0.69
52 Week High
$9.48
$2.97

Technical Indicators

Market Signals
Indicator
JFU
LITS
Relative Strength Index (RSI) 51.22 51.36
Support Level $2.06 $0.97
Resistance Level $2.94 $1.11
Average True Range (ATR) 0.25 0.07
MACD -0.02 0.00
Stochastic Oscillator 52.17 34.01

Price Performance

Historical Comparison
JFU
LITS

About JFU 9F Inc.

9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: